Further recognition of A2A adenosine receptor (A2AR) deficiency in promoting autoimmune diseases, and the association of A2B adenosine receptor (A2BR) overexpression with poor prognosis and survival in cancer, opens the door for pioneering new drugs targeting this pathway (16, 17). Here, ADORA2A is linked to autoimmune disease.